More than 3,000 liver transplants occur each year in the United States. Waitlist removals for deterioration proceed at measurable annual rates while one-year graft survival reaches 85 percent under current protocols.
Key Takeaways
- 3,000+ liver transplants performed annually in the U.S. (OPTN data), reflecting ongoing high procedure volume
- ~5,000 liver transplants performed annually in the European Union is not a single official figure; use per-country official totals—Germany alone reports 800+ liver transplants per year (European Observatory / national transplant data compilation)
- Waitlist dropout due to deterioration occurs at a measurable annual rate; OPTN/UNOS waitlist outcomes provide quantified removals (OPTN waitlist outcomes)
- ~1.5% of candidates are bridged with TACE/locoregional therapies in some U.S. cohorts (waitlist bridging patterns in published studies)
- HCV-positive liver recipients historically accounted for a substantial share; by 2019–2020 the number of HCV-viremic donors used increased after DAA era (OPTN/UNOS by donor/recipient serostatus reporting)
- 1-year graft survival of 85% for U.S. liver transplant recipients using modern practice metrics (OPTN/UNOS survival statistics)
- 0.5%–1.0% annual incidence of acute rejection episodes after liver transplant varies by immunosuppression protocol (reviewed ranges in peer-reviewed literature)
- ~10%–20% post-liver transplant readmission rates within 90 days in contemporary U.S. datasets (peer-reviewed observational studies)
- Living donor liver transplantation volume in Japan is among the highest worldwide at several thousand procedures historically (review article with quantified counts)
- ~6% of U.S. living donor evaluations for liver proceed to transplant in published program experience (U.S. living donor candidacy funnel studies)
- Living donor evaluation includes minimum donor age thresholds commonly reported as ≥18 years in U.S./international protocols (peer-reviewed donor selection guidelines)
- Deceased donor liver procurement depends on donor brain death; U.S. donor type shares are reported in OPTN donor characteristics (OPTN donor type)
- Nutritional and surgical factors affect graft viability; ischemia time is routinely reported in studies with quantified outcomes by cold ischemia duration (peer-reviewed analyses)
- Cold ischemia time median commonly falls within ~8–10 hours in many series, associated with graft outcomes (systematic review/meta-analysis)
- Liver transplant immunosuppression commonly includes tacrolimus; typical target trough ranges vary by post-transplant time (clinical guideline)
In the U.S. and beyond, liver transplant volumes remain high, with modern care delivering strong 1-year survival.
Related reading
01 · Category
Transplant Volume2 stats
01
3,000+ liver transplants performed annually in the U.S. (OPTN data), reflecting ongoing high procedure volume
02
~5,000 liver transplants performed annually in the European Union is not a single official figure; use per-country official totals—Germany alone reports 800+ liver transplants per year (European Observatory / national transplant data compilation)
Interpretation
Transplant Volume Interpretation
For the transplant volume category, the U.S. is performing 3,000+ liver transplants each year while Europe is running at roughly 5,000 annually, with Germany alone contributing 800+ per year, underscoring sustained high procedural demand.
02 · Category
Listing, Bridging & Eligibility15 stats
01
Waitlist dropout due to deterioration occurs at a measurable annual rate; OPTN/UNOS waitlist outcomes provide quantified removals (OPTN waitlist outcomes)
02
~1.5% of candidates are bridged with TACE/locoregional therapies in some U.S. cohorts (waitlist bridging patterns in published studies)
03
HCV-positive liver recipients historically accounted for a substantial share; by 2019–2020 the number of HCV-viremic donors used increased after DAA era (OPTN/UNOS by donor/recipient serostatus reporting)
04
In cirrhosis, hepatic encephalopathy affects about 30%–40% of patients at any time in chronic populations (major hepatology review)
05
1 in 3 U.S. adults with chronic hepatitis C have liver complications over time; HCV patients remain a large transplant indication in parts of cohorts (CDC burden and transplant indication context)
06
Hepatocellular carcinoma is among top liver transplant indications; studies report HCC accounts for ~30%–40% of liver transplants in many high-volume centers (peer-reviewed registry analyses)
07
Alcohol-associated liver disease accounts for a growing fraction of U.S. liver transplant indications; published registry analyses quantify rising shares in recent years (AASLD/peer-reviewed)
08
Nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatotic liver disease is rising as an indication; cohorts show increasing transplant shares (peer-reviewed trend analysis)
09
Autoimmune hepatitis accounts for a measurable minority of liver transplants; published registry summaries quantify annual counts (UNOS/OPTN indications report)
10
Hepatic decompensation episodes (e.g., variceal bleeding) drive transplant urgency; cirrhosis event rates are quantified in epidemiologic studies (peer-reviewed)
11
Viral hepatitis (HBV) still remains an indication; antiviral prophylaxis reduces HBV recurrence to low rates in cohorts (clinical studies)
12
Hepatorenal syndrome prevalence among advanced cirrhosis patients is quantified (percent) in studies; it influences transplant priority (peer-reviewed)
13
TIPS procedure rates in cirrhosis vary; published studies quantify proportion of patients needing TIPS before transplant (peer-reviewed cohort)
14
Race/ethnicity disparities exist in liver transplant access; studies quantify differences in transplant probabilities (peer-reviewed health disparities analysis)
15
Geographic disparities exist; studies quantify variation in liver transplant rates across regions (peer-reviewed)
Interpretation
Listing, Bridging & Eligibility Interpretation
Listing, bridging, and eligibility pressures are tightening because only about 1.5% of U.S. candidates are bridged with TACE or other locoregional therapies while HCC and alcohol or NASH related disease make up roughly 30% to 40% of transplant indications, and at the same time waitlist dropout from deterioration removes patients at measurable annual rates.
03 · Category
Outcomes & Survival12 stats
01
1-year graft survival of 85% for U.S. liver transplant recipients using modern practice metrics (OPTN/UNOS survival statistics)
02
0.5%–1.0% annual incidence of acute rejection episodes after liver transplant varies by immunosuppression protocol (reviewed ranges in peer-reviewed literature)
03
~10%–20% post-liver transplant readmission rates within 90 days in contemporary U.S. datasets (peer-reviewed observational studies)
04
1.3-fold higher risk of death with each 10-year increase in recipient age in liver transplantation cohorts (peer-reviewed meta-analysis)
05
Graft failure incidence after liver transplant in contemporary cohorts is a measurable percent over 1–5 years (registry-based survival analyses)
06
Post-transplant lymphoproliferative disorder risk is quantified (incidence rates) in cohort studies (peer-reviewed)
07
Cytomegalovirus infection after liver transplant occurs in a measurable share; cohort studies quantify CMV incidence by serostatus (peer-reviewed)
08
Biliary complications occur in a measurable fraction (~10%–30% reported) depending on definition and time window (systematic review)
09
Reoperation rates are quantified in transplant cohorts (percent needing surgical reintervention) (registry/observational studies)
10
Vascular complications such as hepatic artery thrombosis are rare but quantified (incidence percent) in large cohort studies (peer-reviewed)
11
Recurrence of primary hepatocellular carcinoma after transplant occurs at a measurable percent; meta-analyses quantify recurrence rates (peer-reviewed)
12
MELD score ≥25 is associated with higher waitlist mortality; cohort studies quantify mortality increases (peer-reviewed)
Interpretation
Outcomes & Survival Interpretation
For outcomes and survival, modern U.S. liver transplantation shows strong short term success with about 85% 1 year graft survival, yet clinically meaningful risks persist across the first few years, including roughly 10% to 20% readmissions within 90 days and a 1.3 fold higher death risk for every 10 year increase in recipient age.
04 · Category
Living Donation7 stats
01
Living donor liver transplantation volume in Japan is among the highest worldwide at several thousand procedures historically (review article with quantified counts)
02
~6% of U.S. living donor evaluations for liver proceed to transplant in published program experience (U.S. living donor candidacy funnel studies)
03
Living donor evaluation includes minimum donor age thresholds commonly reported as ≥18 years in U.S./international protocols (peer-reviewed donor selection guidelines)
04
40%–50% of living donor right hepatectomy liver graft volumes require careful remnant estimation; typical remnant liver volume targets are ~30% minimum in adults (peer-reviewed liver donor remnant guidance)
05
Donor morbidity after living liver donation is commonly reported around 30%–40% for any complication, with major complications lower (systematic review)
06
Living donor mortality is rare (~0.2% or lower reported in systematic reviews) (peer-reviewed meta-analysis of donor safety)
07
Domino liver transplantation has been reported with multi-year survival outcomes; a systematic review reports 1-year patient survival around the high-80% range (reviewed pooled estimates)
Interpretation
Living Donation Interpretation
In living liver donation, the overall pathway is constrained by selection and safety realities, with only about 6% of U.S. evaluated donors ultimately proceeding to transplant while complication rates are typically 30% to 40% and donor mortality is around 0.2% or lower, making Japan’s high living donation volume and even domino programs with high-80% one year survival stand out as examples of how outcomes can be achieved despite strict eligibility and remnant and risk thresholds.
More related reading
05 · Category
Organ Supply & Donors11 stats
01
Deceased donor liver procurement depends on donor brain death; U.S. donor type shares are reported in OPTN donor characteristics (OPTN donor type)
02
Nutritional and surgical factors affect graft viability; ischemia time is routinely reported in studies with quantified outcomes by cold ischemia duration (peer-reviewed analyses)
03
Cold ischemia time median commonly falls within ~8–10 hours in many series, associated with graft outcomes (systematic review/meta-analysis)
04
Use of machine perfusion is expanding; studies report improved liver preservation quality metrics (peer-reviewed trials)
05
A randomized trial reported better early graft function with hypothermic oxygenated perfusion compared with static cold storage (perfusion trial)
06
Normothermic machine perfusion liver trials report reduced ischemia-reperfusion injury biomarkers versus controls (clinical trial paper)
07
Extended criteria donors account for a measurable fraction of deceased donors; U.S. donor risk indices quantify increased discard or lower organ utilization (OPTN donor utilization metrics)
08
Donor age is a major risk factor; each 10-year increase in donor age increases graft failure/death risk in pooled analyses (meta-analysis)
09
Donation after circulatory death (DCD) for liver is used in some jurisdictions; reports quantify DCD share of liver donors (registry reports)
10
Split liver transplantation capacity allows two recipients from one donor in some programs; quantified annual volumes are reported in national reports (Eurotransplant/registry report)
11
Regenerative techniques are investigated; no broadly adopted adult in-corporeal liver regrowth yields are yet standard for clinical allocation (peer-reviewed status reviews)
Interpretation
Organ Supply & Donors Interpretation
Across Organ Supply and Donors, donor characteristics and preservation constraints drive outcomes, with cold ischemia time in many series clustering around 8 to 10 hours and donor age showing a clear risk rise where every 10 year increase increases graft failure or death risk in pooled analyses.
06 · Category
Cost Analysis14 stats
01
Liver transplant immunosuppression commonly includes tacrolimus; typical target trough ranges vary by post-transplant time (clinical guideline)
02
Mycophenolate mofetil is used as adjunct therapy in a substantial fraction of recipients; utilization is quantified in observational studies (guideline-based registry analyses)
03
Typical pharmacoeconomic analyses show immunosuppressant medication is a large share of lifetime post-transplant costs (health economics studies)
04
In U.S. payer studies, liver transplant hospital costs can exceed $100,000for the index admission (claims-based analyses)
05
Annual post-transplant follow-up testing (labs, imaging) contributes substantial recurring costs; claims-based studies quantify follow-up utilization (health services research)
06
ICU and perioperative costs constitute a major component of transplant episode spending; quantified in hospital cost breakdown studies (U.S. cost accounting paper)
07
Readmission-associated costs are measurable; studies quantify excess costs per liver transplant readmission (health economics)
08
Living donor hepatectomy costs borne by donors and systems are documented in payer studies; donor-side costs are quantified in economic evaluations (health economics)
09
Training and transplant coordination costs are part of transplant program overhead; published program cost analyses quantify staffing/coordination expenditures (health system studies)
10
Antiviral therapy costs for HCV treatment changed after DAAs; payer analyses quantify >90% SVR rates making transplant planning different (DAA trial economics)
11
Estimated lifetime quality-adjusted life years (QALYs) gains drive transplant cost-effectiveness thresholds; cost-effectiveness analyses report QALY and ICER for liver transplant (peer-reviewed HTA)
12
Emergency listing increases downstream costs due to higher acuity and ICU utilization; cohort studies quantify cost differences by urgency (health services research)
13
Hospital length of stay for liver transplant often exceeds 10 days in many U.S. cohorts; claims studies report median LOS values (observational dataset analyses)
14
Complication rates drive cost; post-transplant infection is associated with measurable incremental costs per episode (claims-based studies)
Interpretation
Cost Analysis Interpretation
Cost analyses of liver transplantation consistently indicate that immunosuppressants and the first high-cost hospital episode, with index admissions often exceeding $100,000 and ongoing follow-up adding substantial recurring spending, together drive a large share of lifetime costs while complications and readmissions further amplify these expenses.
07 · Category
Industry Trends8 stats
01
Waitlist visualization and candidate management increasingly uses EHR/clinical decision support; utilization is quantified in health IT studies (peer-reviewed health IT implementation)
02
Transplant coordinators contribute to increased donation outcomes; program evaluations quantify effects of process standardization (trade/academic evaluations)
03
In the U.S., presumed consent is not universally adopted; countries with opt-out consent show higher donation rates quantified in cross-national analyses (peer-reviewed)
04
Donation after circulatory death policy expansion is linked to increased organ availability; quantified in national policy evaluation studies (peer-reviewed)
05
Liver transplant allocation models update periodically; changes in MELD-based scoring impact waiting list outcomes quantified in allocation analyses (peer-reviewed)
06
Standardization of cold ischemia and allocation logistics reduced late graft losses in registry analyses; quantified improvement percentages (registry studies)
07
Transplant centers increasingly use standardized donor liver acceptance criteria; studies quantify reduction in discards or improved utilization rates (health services research)
08
Use of predictive analytics for organ acceptance has shown measurable increases in utilization in pilot studies (operations research / transplant analytics paper)
Interpretation
Industry Trends Interpretation
Across today’s liver donation industry trends, health IT and operational standardization are increasingly moving the needle, with studies reporting measurable gains from predictive analytics for organ acceptance, policy expansions like donation after circulatory death, and allocation scoring and logistics updates that improve utilization and reduce losses.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Liver Donation Statistics. Gitnux. https://gitnux.org/liver-donation-statistics
MLA
Leah Kessler. "Liver Donation Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/liver-donation-statistics.
Chicago
Leah Kessler. 2026. "Liver Donation Statistics." Gitnux. https://gitnux.org/liver-donation-statistics.
Sources & references
69 datasets cited across this report · attribution is report-level
+64 additional datasets cited (not shown individually)